Format

Send to

Choose Destination
J Neurol Neurosurg Psychiatry. 2016 Mar;87(3):275-9. doi: 10.1136/jnnp-2014-309964. Epub 2015 Mar 26.

Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy.

Author information

1
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
2
Department of Neurology, Dokkyo Medical University, Tochigi, Japan.
3
Department of Neurology, Hokuyukai Neurological Hospital, Sapporo, Japan.
4
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Abstract

OBJECTIVE:

Sialylation in Fc portion of IgG plays a crucial role in the pathogenesis of autoimmune diseases and the working mechanism of intravenous immunoglobulin (IVIG). We aim to test whether IgG-Fc sialylation is a biomarker of disease activity for chronic inflammatory demyelinating polyneuropathy (CIDP).

METHODS:

By using specific lectins for sialylation, galactosylation and agalactosylation, lectin-enzyme assay and lectin blotting with pretreatment of IgG degradating enzyme of Streptococcus pyogenes were performed to compare the glycosylation levels of serum IgG-Fc (1) between patients of untreated CIDP (n=107) and normal control subjects (n=27), (2) among patients with untreated CIDP of different clinical severities and (3) before and after IVIG treatment of patients with CIDP (n=12).

RESULTS:

Sialylation and galactosylation of IgG-Fc were significantly reduced in patients with CIDP than normal control subjects (p=0.003 and 0.033, respectively), whereas agalactosylation was increased in CIDP (p=0.21). Ratios of sialylated/agalactosylated IgG-Fc levels were significantly reduced in CIDP (p<0.001) and inversely related to disease severity (p=0.044). After IVIG treatment, levels of sialylated IgG-Fc significantly increased (p=0.003).

CONCLUSIONS:

Sialylation of IgG-Fc is reduced in CIDP. Its level correlated with clinical severity and increased after IVIG treatment. Sialylated as well as ratio of sialylated/agalactosylated IgG-Fc could be new measures to monitor the disease severity and treatment status in CIDP.

KEYWORDS:

IMMUNOLOGY; NEUROPATHY

PMID:
25814494
DOI:
10.1136/jnnp-2014-309964
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center